Gujarat Themis Biosyn Ltd
BSE:506879
Gujarat Themis Biosyn Ltd
Cost of Revenue
Gujarat Themis Biosyn Ltd
Cost of Revenue Peer Comparison
Competitive Cost of Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Gujarat Themis Biosyn Ltd
BSE:506879
|
Cost of Revenue
-₹609.5m
|
CAGR 3-Years
-96%
|
CAGR 5-Years
-20%
|
CAGR 10-Years
-13%
|
|
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
|
Cost of Revenue
-₹80.1B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
N/A
|
|
Cipla Ltd
NSE:CIPLA
|
Cost of Revenue
-₹88.3B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-9%
|
|
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
|
Cost of Revenue
-₹105.3B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-15%
|
|
Zydus Lifesciences Ltd
NSE:ZYDUSLIFE
|
Cost of Revenue
-₹63.1B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-9%
|
|
M
|
Mankind Pharma Ltd
NSE:MANKIND
|
Cost of Revenue
-₹30.7B
|
CAGR 3-Years
-15%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Gujarat Themis Biosyn Ltd's Cost of Revenue?
Cost of Revenue
-609.5m
INR
Based on the financial report for Dec 31, 2023, Gujarat Themis Biosyn Ltd's Cost of Revenue amounts to -609.5m INR.
What is Gujarat Themis Biosyn Ltd's Cost of Revenue growth rate?
Cost of Revenue CAGR 10Y
-13%
Over the last year, the Cost of Revenue growth was -82%. The average annual Cost of Revenue growth rates for Gujarat Themis Biosyn Ltd have been -96% over the past three years , -20% over the past five years , and -13% over the past ten years .